Stock Taper
SCREENER COMPARE ANY 2 STOCKS
VKTX
VIKING THERAPEUTICS, INC.
NASDAQ
$32.16
▼ DOWN 5.02% (-1.70)

KEY STATISTICS

Market Cap$3.75 B
52w High$43.15
52w Low$22.96
Dividend Yield—
Frequency—
P/E-6.90
Volume2.38M
Shares Out.116.65M

COMPANY

LEADERSHIP

Brian Lian
CHIEF EXECUTIVE
Brian Lian

COMPENSATION 2026

Salary$672,000
Stock Awards$17,756,817
Incentive Plan Pay$373,000
All Other Comp.$0
Total$21,269,833

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 28, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
65

PRICE TARGET

Target High$101.00
Target Low$83.00
Target Median$95.00
Target Consensus$93.60

UPCOMING EARNINGS

DateOct 28, 2026
DayWednesday
Rev. Est.—
OCT
28
WED

PRICE

$32.16 ▼ DOWN 5.02% (−$1.70)
$32.25$33.00$33.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM32.16

About Viking Therapeutics, Inc.

https://www.vikingtherapeutics.com ↗

Viking Therapeutics, a San Diego-based clinical-stage biopharma, develops novel therapies for metabolic and endocrine disorders, including VK2809 for NASH/NAFLD and VK5211 for hip fracture recovery.

INDUSTRY

Biotechnology

A PRODUCT VIKING THERAPEUTICS, INC. IS KNOWN FOR

VK2735
VK2735

VK2735 is Viking Therapeutics' leading experimental drug, a dual GLP-1 and GIP receptor agonist in Phase 3 trials, developed as an injectable and oral treatment for obesity.

COMPETITORS

COMPETITOR
AMGN COMPARE
LLY COMPARE
MDGL COMPARE
NVO COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
153
LISTED HERE
26
RANKED BY POSITION SIZE
XBI
1.08% · 3.8M
VTI
0.00% · 3.5M
SCHA
0.08% · 553.4K
IWR
0.03% · 459.9K
DFMC
0.15% · 350.0K
LABU
0.74% · 138.7K
OZEM
4.67% · 93.8K
FHLC
0.05% · 52.7K
BBSC
0.14% · 31.5K
PRFZ
0.03% · 30.7K
JHSC
0.14% · 30.5K
MID
0.89% · 23.0K
DUNK
0.42% · 21.7K
ISMD
0.17% · 17.2K
CURE.AX
1.08% · 11.8K
BBC
0.71% · 10.9K
RECS
0.01% · 9.5K
FORH
1.46% · 8.7K
HRTS
0.48% · 8.4K
THNR
4.32% · 7.2K
WBIO.L
0.72% · 7.0K
NIXT
0.45% · 6.1K
BKSE
0.16% · 4.4K
STXK
0.15% · 4.0K
RFLR
0.13% · 4.0K
ESSC
0.31% · 3.5K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
46.54%
HOLDERS
584
TOP 12 OF 584 · RANKED BY POSITION SIZE
Vanguard Group Inc
10.0M sh · $262.78M
Blackrock, Inc.
6.9M sh · $223.88M
Fmr LLC
6.6M sh · $230.7M
Blackrock Inc.
6.0M sh · $319.45M
State Street Corp
5.6M sh · $218.71M
Two Sigma Investments, LP
4.4M sh · $144.22M
Morgan Stanley
3.7M sh · $98M
Jpmorgan Chase & Co
2.6M sh · $67.73M
Ameriprise Financial Inc
2.2M sh · $84.11M
Two Sigma Advisers, LP
2.1M sh · $74.91M
Susquehanna International Group, Llp
2.1M sh · $55.18M
Geode Capital Management, LLC
2.1M sh · $81.87M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Kelly-Gemmell Dorothy Elizabeth
Purchase · 40.8K shares
2026-08-01
★
Kelly-Gemmell Dorothy Elizabeth
— · —
2026-08-01
★
DIRECTOR
Kelly-Gemmell Dorothy Elizabeth
Purchase · 6.3K shares
2026-08-01
★
DIRECTOR, OFFICER: PRESIDENT & CEO
Lian Brian
Sale · 148.5K shares
2026-07-29

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 3
BUY 3
6 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT Canaccord Genuity BUY BTIG BUY Cantor Fitzgerald OVERWEIGHT HC Wainwright & Co. BUY Morgan Stanley OVERWEIGHT

SECTORS PEERS

PEERPRICE
KYMR$118.15COMPARE
PRAX$344.75COMPARE
CRNX$84.84COMPARE
IMVT$41.20COMPARE
LGND$280.49COMPARE
ACAD$29.11COMPARE
NAMS$25.90COMPARE
AAPG$18.28COMPARE